Kiniksa Pharmaceuticals International, plc financial data

Symbol
KNSA on Nasdaq
Location
23 Old Bond Street, Floor 3, London, United Kingdom
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Oct 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 360 % -4.19%
Quick Ratio 31.4 % -20.6%
Debt-to-equity 32.6 % +41.5%
Return On Equity 7.46 %
Return On Assets 5.63 %
Operating Margin 6.38 %

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 697M USD +36.7%
Weighted Average Number of Shares Outstanding, Basic 74.7M shares +4.17%
Weighted Average Number of Shares Outstanding, Diluted 80M shares +11.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 181M USD +61.2%
Revenue from Contract with Customer, Excluding Assessed Tax 598M USD +55.7%
Research and Development Expense 97.5M USD +1.04%
Operating Income (Loss) 38.2M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 48.6M USD
Income Tax Expense (Benefit) 12.7M USD +58.8%
Net Income (Loss) Attributable to Parent 35.9M USD
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 175M USD +79.6%
Cash, Cash Equivalents, and Short-term Investments 352M USD +57.3%
Accounts Receivable, after Allowance for Credit Loss, Current 51.7M USD +108%
Inventory, Net 41.4M USD +44.3%
Assets, Current 476M USD +52.8%
Deferred Income Tax Assets, Net 201M USD -3.22%
Property, Plant and Equipment, Net 1.66M USD +195%
Operating Lease, Right-of-Use Asset 10.1M USD -9.21%
Other Assets, Noncurrent 8.29M USD +5.54%
Assets 712M USD +28.3%
Accounts Payable, Current 6.15M USD -26.2%
Employee-related Liabilities, Current 17M USD +30.2%
Accrued Liabilities, Current 30.9M USD -23.4%
Contract with Customer, Liability, Current 12K USD -99.7%
Liabilities, Current 124M USD +28.8%
Contract with Customer, Liability, Noncurrent 31.8M USD +169%
Operating Lease, Liability, Noncurrent 7.02M USD -18%
Other Liabilities, Noncurrent 14.5M USD +640%
Liabilities 177M USD +49.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -155K USD -278%
Retained Earnings (Accumulated Deficit) -476M USD +7.01%
Stockholders' Equity Attributable to Parent 535M USD +22.5%
Liabilities and Equity 712M USD +28.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 22.3M USD +460%
Net Cash Provided by (Used in) Financing Activities 2.77M USD -23.4%
Net Cash Provided by (Used in) Investing Activities -51.5M USD -302%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 175M USD +79.6%
Deferred Tax Assets, Valuation Allowance 657M USD +1320%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure
Deferred Tax Assets, Gross 879M USD +227%
Operating Lease, Liability 9.86M USD
Depreciation 163K USD -72.7%
Payments to Acquire Property, Plant, and Equipment 99K USD +17.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 35.8M USD
Lessee, Operating Lease, Liability, to be Paid 11.1M USD
Property, Plant and Equipment, Gross 9.47M USD +9.31%
Operating Lease, Liability, Current 2.7M USD +32.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.44M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.55M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure
Deferred Income Tax Expense (Benefit) 4.23M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.29M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.12M USD
Deferred Tax Assets, Operating Loss Carryforwards 85.4M USD +7468%
Unrecognized Tax Benefits 13.4M USD +646%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.04M USD
Additional Paid in Capital 1.01B USD +6.59%
Amortization of Intangible Assets 250K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 211M USD -3.71%
Share-based Payment Arrangement, Expense 35.1M USD +16.2%